Results 21 to 30 of about 14,132 (178)

Intraosseous mucoepidermoid carcinoma of mandible - A rare menace in mandible

open access: yesAdvances in Oral and Maxillofacial Surgery, 2023
Salivary gland tumors makes up 3–4% of all head and neck cancers, mucoepidermoid carcinoma is a malignant locally recurrent variant of salivary gland carcinoma.
P. Nagendra   +4 more
doaj   +1 more source

Central mucoepidermoid carcinoma of the maxilla: a case report

open access: yesB-ENT, 2010
Central Mucoepidermoid Carcinoma of the Maxilla: A Case Report. Background and objective: Primary mucoepidermoid carcinoma of the jaw is a rare lesion, comprising 2-3% of all mucoepidermoid carcinomas reported in literature.
W. Zhao, H. Wang, X. Teng, J. Liu
doaj   +2 more sources

Central mucoepidermoid carcinoma of the mandible: A case report

open access: yesNigerian Dental Journal, 2011
Primary central salivary gland carcinomas of the mandible are uncommon neoplasms. Mucoepidermoid carcinoma is a distinct pathologic entity of the salivary glands and comprises 5-10% of all salivary gland tumours.
S. A. Ogunmuyiwa   +3 more
doaj   +1 more source

Mucoepidermoid carcinoma of the thymus incidentally diagnosed following two-years of non-productive cough

open access: yesRadiology Case Reports, 2021
Mucoepidermoid carcinoma of the thymus is a rare primary thymic carcinoma. Radiologic imaging of this malignancy is rarely reported in literature.
Ryan Thibodeau, MD, MPH   +6 more
doaj   +1 more source

Infarcted Warthin tumor with mucoepidermoid carcinoma-like metaplasia: a case report and review of the literature

open access: yesJournal of Medical Case Reports, 2019
Background Warthin tumor is a common, benign, painless salivary gland neoplasm. Rarely, Warthin tumors show large areas of squamous metaplasia; such Warthin tumors are called metaplastic or infarcted Warthin tumors because they are occasionally ...
Kenji Yorita   +5 more
doaj   +1 more source

Clinical Features and Differential Diagnoses in Laryngeal Mucoepidermoid Carcinoma

open access: yesClinical Medicine Insights: Pathology, 2012
Mucoepidermoid carcinoma is the most common malignant tumor of salivary glands. However, it is a rare entity in larynx. Laryngeal cases are frequently misdiagnosed with other malignancies and they are under-reported.
Sepideh Mokhtari, Saeedeh Mokhtari
doaj   +1 more source

Fine‐Needle Aspiration of Salivary Gland Tumors With Low‐Grade Oncocytic Features: Focusing on Oncocytoma Versus Oncocytic Mucoepidermoid Carcinoma

open access: yesDiagnostic Cytopathology, EarlyView.
ABSTRACT Background Salivary gland fine‐needle aspirates (FNAs) with low‐grade oncocytic features are diagnostically challenging due to the substantial morphologic overlap between benign oncocytic tumors and their malignant mimickers. This study evaluates the diagnostic discriminators, performance, and risk of malignancy of these lesions using the ...
Lois Araneta   +2 more
wiley   +1 more source

Dental Rehabilitation of the Scapular Tip in Maxillary Reconstruction

open access: yesHead &Neck, EarlyView.
ABSTRACT Introduction The fibula‐free flap has traditionally been utilized to perform dental rehabilitation following maxillectomy. The purpose of this study is to present our experience with dental implantation of the scapula–tip‐free flap in midface reconstruction.
Leba M. Sarkis   +9 more
wiley   +1 more source

Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus

open access: yesCellular Physiology and Biochemistry, 2018
Background/Aims: Protein phosphatase 2A (PP2A) is a ubiquitous serine/threonine phosphatase that mediates cell cycle regulation and metabolism. Mounting evidence has indicated that PP2A inhibition exhibits considerable anticancer potency in multiple ...
Limin Liu   +13 more
doaj   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy